RESUMEN
Mucuna pruriens possesses significantly higher antiparkinson activity compared with levodopa in the 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease. The present study evaluated the neurorestorative effect of Mucuna pruriens cotyledon powder on the nigrostriatal tract of 6-OHDA lesioned rats. Mucuna pruriens cotyledon powder significantly increased the brain mitochondrial complex-I activity but did not affect the total monoamine oxidase activity (in vitro). Unlike synthetic levodopa treatment, Mucuna pruriens cotyledon powder treatment significantly restored the endogenous levodopa, dopamine, norepinephrine and serotonin content in the substantia nigra. Nicotine adenine dinucleotide (NADH) and coenzyme Q-10, that are shown to have a therapeutic benefit in Parkinson's disease, were present in the Mucuna pruriens cotyledon powder. Earlier studies showed that Mucuna pruriens treatment controls the symptoms of Parkinson's disease. This additional finding of a neurorestorative benefit by Mucuna pruriens cotyledon powder on the degenerating dopaminergic neurons in the substantia nigra may be due to increased complex-I activity and the presence of NADH and coenzyme Q-10.
Asunto(s)
Mucuna , Fármacos Neuroprotectores/farmacología , Enfermedad de Parkinson/tratamiento farmacológico , Fitoterapia , Animales , Relación Dosis-Respuesta a Droga , Levodopa/administración & dosificación , Levodopa/farmacología , Levodopa/uso terapéutico , Masculino , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/uso terapéutico , Oxidopamina , Enfermedad de Parkinson/patología , Componentes Aéreos de las Plantas , Distribución Aleatoria , Ratas , Ratas Sprague-DawleyRESUMEN
HP-200, which contains Mucuna pruriens endocarp, has been shown to be effective in the treatment of Parkinson's disease. Mucuna pruriens endocarp has also been shown to be more effective compared to synthetic levodopa in an animal model of Parkinson's disease. The present study was designed to elucidate the long-term effect of Mucuna pruriens endocarp in HP-200 on monoaminergic neurotransmitters and its metabolite in various regions of the rat brain. HP-200 at a dose of 2.5, 5.0 or 10.0 g/kg/day was mixed with rat chow and fed daily ad lib to Sprague-Dawley rats (n = 6 for each group) for 52 weeks. Controls (n = 6) received no drug. Random assignment was made for doses and control. The rats were sacrificed at the end of 52 weeks and the neurotransmitters were analyzed in the cortex, hippocampus, substantia nigra and striatum. Oral administration of Mucuna pruriens endocarp in the form of HP-200 had a significant effect on dopamine content in the cortex with no significant effect on levodopa, norepinephrine or dopamine, serotonin, and their metabolites- HVA, DOPAC and 5-HIAA in the nigrostriatal tract. The failure of Mucuna pruriens endocarp to significantly affect dopamine metabolism in the striatonigral tract along with its ability to improve Parkinsonian symptoms in the 6-hydorxydopamine animal model and humans may suggest that its antiparkinson effect may be due to components other than levodopa or that it has an levodopa enhancing effect.
Asunto(s)
Antiparkinsonianos/farmacología , Mucuna , Neurotransmisores/metabolismo , Fitoterapia , Extractos Vegetales/farmacología , Administración Oral , Animales , Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/uso terapéutico , Encéfalo/efectos de los fármacos , Encéfalo/patología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Distribución Aleatoria , Ratas , Ratas Sprague-DawleyRESUMEN
The neurochemical mechanisms of electroconvulsive therapy (ECT) are not fully elucidated. We examined the effects of electroconvulsive shock (ECS) on brain gamma-aminobutyric acid (GABA) systems. Male Wistar-Furth rats were given ECS via auricular (ear-clip) or corneal electrodes once per day (120 V, 0.5 s) for 10 consecutive days. Two groups of sham ECS rats, one for auricular placement and one for corneal placement, served as controls. Current was measured and seizures were scored during each ECS trial. Rats receiving ECS via corneal electrodes were subjected to more electrical current compared to rats treated with auricular electrodes. Although both groups exhibited behavioral seizures of similar duration, electrode placement had a differential influence on the expression of tonic hindlimb extension and clonic hindlimb activity over the 10-day regimen. GABA levels were increased in all brain regions examined in rats treated with auricular electrodes except the hippocampus and nucleus accumbens; rats treated with corneal electrodes exhibited GABA increases in the hippocampus, frontal cortex, hypothalamus, and olfactory bulbs; a significant decrease in nucleus accumbens; and no change in the substantia nigra and striatum. The mode of ECS delivery selectively alters the pattern of regional alterations of brain GABA level induced by ECS. This effect may be a function of current intensity or localization.